PDCD1 and cancer: Programmed cell death 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) inhibitors, which target the PD-1/PD-L1 axis and reverse the negative regulators of T cells, are most promising and have been applied to the treatment of several types of cancers [1–5].